17 results on '"Storozenko, J."'
Search Results
2. Prevalence of Viral Hepatitis C among Healthcare Professionals in Intensive Care Units in 2015: a CrossSectional Study from Latvia
- Author
-
Tolmane I, Fridrihsone E, Aivars L, Storozenko J, Rozentale B, Lapke L, and Raimonds S
- Subjects
medicine.medical_specialty ,Health professionals ,business.industry ,Intensive care ,Family medicine ,medicine ,Viral hepatitis ,medicine.disease ,business - Published
- 2017
3. Status, quality and specific needs of Zika virus (ZIKV) diagnostic capacity and capability in National Reference Laboratories for arboviruses in 30 EU/EEA countries, MAY 2016
- Author
-
Mögling, R. (Ramona), Zeller, H. (Hervé), Revez, J. (J.), Koopmans D.V.M., M.P.G. (Marion), Reusken, C.B.E.M. (Chantal), Aberle, S.W. (Stephan), Esbroeck, M. (M.) van, Christova, I., Vilibic-Cavlek, T. (Tatjana), Richter, J. (Jan), Zelena, H. (Hana), Fomsgaard, A. (Anders), Jääskeläinen, A. (Anne), Brichler, S. (Segolene), Illiaquer, M. (Marina), Gonfrier, G. (Geraldine), Leparc-Goffart, I. (Isabelle), Poveda, J.-D. (Jean-Dominique), Hober, D. (D.), Fleury, H. (Hervé), Fafi-Kremer, S. (Samira), Foulongne, V. (V.), Henquell, C. (Cécile), Leveque, N. (Nicolas), Carles, M.J. (Marie Josee), Mansuy, J.M. (J. M.), Schmidt-Chanasit, J. (Jonas), Nitsche, A., Papa, A. (Anna), Mentis, A. (Andreas), Takacs, M. (Maria), Love, A. (Arthur), Connell, J. (Jeff), Venturi, G. (Giulietta), Storozenko, J. (Jelena), Griskevicius, A. (Algirdas), Opp, M. (Matthias), Barbara, C. (Christopher), Reimerink, J.H.J. (Johan), Dudman, S.G. (Susanne Gjeruldsen), Pancer, K. (Katarzyna), Alves, M.J. (M. João), Ceianu, C.S., Ticha, E. (Elena), Županc, T.A. (Tatjana Avšič), Sanchez-Seco, M.P. (Maria Paz), Tolfvenstam, T. (Thomas), Aarons, E., Mögling, R. (Ramona), Zeller, H. (Hervé), Revez, J. (J.), Koopmans D.V.M., M.P.G. (Marion), Reusken, C.B.E.M. (Chantal), Aberle, S.W. (Stephan), Esbroeck, M. (M.) van, Christova, I., Vilibic-Cavlek, T. (Tatjana), Richter, J. (Jan), Zelena, H. (Hana), Fomsgaard, A. (Anders), Jääskeläinen, A. (Anne), Brichler, S. (Segolene), Illiaquer, M. (Marina), Gonfrier, G. (Geraldine), Leparc-Goffart, I. (Isabelle), Poveda, J.-D. (Jean-Dominique), Hober, D. (D.), Fleury, H. (Hervé), Fafi-Kremer, S. (Samira), Foulongne, V. (V.), Henquell, C. (Cécile), Leveque, N. (Nicolas), Carles, M.J. (Marie Josee), Mansuy, J.M. (J. M.), Schmidt-Chanasit, J. (Jonas), Nitsche, A., Papa, A. (Anna), Mentis, A. (Andreas), Takacs, M. (Maria), Love, A. (Arthur), Connell, J. (Jeff), Venturi, G. (Giulietta), Storozenko, J. (Jelena), Griskevicius, A. (Algirdas), Opp, M. (Matthias), Barbara, C. (Christopher), Reimerink, J.H.J. (Johan), Dudman, S.G. (Susanne Gjeruldsen), Pancer, K. (Katarzyna), Alves, M.J. (M. João), Ceianu, C.S., Ticha, E. (Elena), Županc, T.A. (Tatjana Avšič), Sanchez-Seco, M.P. (Maria Paz), Tolfvenstam, T. (Thomas), and Aarons, E.
- Abstract
With international travel, Zika virus (ZIKV) is introduced to Europe regularly. A country’s ability to robustly detect ZIKV introduction and local transmission is important to
- Published
- 2017
- Full Text
- View/download PDF
4. The potential risks and impact of the start of the 2015-2016 influenza season in the WHO European Region: a rapid risk assessment
- Author
-
Tjon‐Kon‐Fat, Raïssa, Meerhoff, Tamara, Nikisins, Sergejs, Pires, João, Pereyaslov, Dmitriy, Gross, Diane, Brown, Caroline, Drishti, A., Hasibra, I., Kota, M., Simaku, A., Sarkisian, S., Torosyan, L., El Belazi, G., Hain, C., Lachner, P., Muchl, R., Popow‐Kraupp, T., Redlberger‐Fritz, M., Strauss, R., Abdullayeva, N., Salimov, O., Gribkova, N., Shimanovich, V., Bossuyt, N., Hombrouck, A., Moreels, S., Thomas, I., an Casteren, ., Bastinac, D., Dedejic Ljubovic, A., Kojic, D., Kovacevic Suljkanovic, M., Kuzmanovic, M., Vukmir Rodic, N., Georgieva, T., Kojouharova, M., Korsun, N., Drazenovic, V., Erceg, M., Kurecic‐Filipovic, S., Simunovic, A., Visekruna, V.V., Bagatzouni, D., Elia, A., Koliou, M., Havlickova, M., Jirincova, H., Kyncl, J., Bragstad, K., Kolsen Fischer, T., Krause, K.L., Mazick, A., Trebbien, R., Dontsenko, I., Dotsenko, L., Pokras, L., Sadikova, O., Ikonen, N., Lyytikainen, O., Murtopuro, S., Ruutu, P., Behillil, S., Belchior, E., Blanchon, T., Bonmarin, I., Bruno, L., Cohen, J.M., Enouf, V., Levy, B.D., Mosnier, A., Turbelin, C., Valette, M., an der Werf, ., Chakhunashvili, G., Machablishvili, A., Zakhashvili, K., Andreas, G., Buda, S., Eckmanns, T., Krause, G., Poggensee, G., Schweiger, B., Kossivakis, A., Malisiovas, N., Mentis, A., Spala, G., Csohan, A., Jankovics, I., Kaszas, K., Molnar, Z., Rozsa, M., Gudnason, T., Löve, A., Sigmundsdottir, G., Coughlan, S., Domegan, L., Duffy, M., Igoe, D., O'Donnell, J., O'Flanagan, D., Waters, A., Kaufman, Z., Mandelboim, M., Bella, A., Donatelli, I., Pompa, M.G., Rizzo, C., Amandosova, D., Kuatbaeva, A., Nusupbaeva, G., Smagulova, M., Smagul, M., Sultanova, M., Otorbaeva, D., Saparova, G., Butirina, R., Nikiforova, R., Storozenko, J., Zamjatina, N., Griskevicius, A., Lipnickiene, V., Muralyte, S., Mossong, J., Opp, M., Barbara, C., Graziella, Z., Maistre, M.J., Melillo, T., Rakocevic, B., Vratnica, Z., Hooiveld, I., de Lange, M., Dijkstra, F., Donker, G., Meijer, A., Rimmelzwaan, G., Teirlinck, A., van der Hoek, W., Dudman, S., Hauge, S.H., Hungnes, O., Kilander, A., Tonnessen, R., Bednarska, K., Brydak, L., Wozniak‐Kosek, A., Zielinski, A., Guiomar, R., Nunes, B., Eder, V., Spinu, C., Alexandrescu, V., Lupulescu, E., Popovici, F., Burtseva, E., Komissarov, A., Smorodintseva, E., Sominina, A., Dimitrijevic, D., Filipovic, S., Staronova, E., Berginc, N., Prosenc, K., Socan, M., Ucakar, V., Grgic Vitek, M., Casas, I., de Lejarazu, R. Ortiz, Larrauri, A., Pozo, F., Vega, T., Ali, M., Brytting, M., Dahl, H., Englund, H., Tegnell, A., Wallensten, A., Wiman, A., Born, R., Cordey, S., Kamolov, M., Bosevska, G., Karadzovski, Z., Kuzmanovska, G., Mikik, V., Korukluoglu, G., Topal, S., Ashyrova, A., Ovliyakulova, G., Demchyshyna, I., Dykhanovska, T., Mironenko, A., Blatchford, O., Carman, W., Coyle, P., Gunson, R., Kearns, C., MacLean, A., Mcmenamin, J., Moore, C., Nugent, C., Pebody, R., Phin, N., Reynolds, A., Smyth, B., Watson, J., Zambon, M., Dzemileva, S., and Rakhimov, R.
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Epidemiology ,Influenza season ,Influenza A(H1N1)pdm09 virus ,influenza A(H1N1)pdm09 virus ,Seasonal influenza ,03 medical and health sciences ,Environmental protection ,Virology ,Environmental health ,Estado de Saúde ,2015–2016 Influenza season ,Public Health, Environmental and Occupational Health ,virus diseases ,1103 Clinical Sciences ,European region ,030112 virology ,Europe ,030104 developmental biology ,Infectious Diseases ,Geography ,1117 Public Health And Health Services ,2015-2016 Influenza season ,Original Article ,seasonal influenza ,Determinantes da Saúde e da Doença ,WHO European Region ,Risk assessment - Abstract
WHO European Region Influenza Network: P.Conde, I. Costa, P. Crostovão, R. Guiomar, B. Nunes, P.Pechirra, A. Rodrigues (Portugal) BACKGROUND: Countries in the World Health Organization (WHO) European Region are reporting more severe influenza activity in the 2015-2016 season compared to previous seasons. OBJECTIVES: To conduct a rapid risk assessment to provide interim information on the severity of the current influenza season METHODS: Using the WHO manual for rapid risk assessment of acute public health events and surveillance data available from Flu News Europe, an assessment of the current influenza season from 28 September 2015 (week 40/2015) up to 31 January 2016 (week 04/2016) was made compared with the 4 previous seasons. RESULTS: The current influenza season started around week 51/2015 with higher influenza activity reported in eastern Europe compared to Western Europe. There is a strong predominance of influenza A(H1N1)pdm09 compared to previous seasons, but the virus is antigenically similar to the strain included in the seasonal influenza vaccine. Compared to the 2014/2015 season, there was a rapid increase in the number of severe cases in eastern European countries with the majority of such cases occurring among adults aged
- Published
- 2016
5. Laboratory capability and surveillance testing for middle east respiratory syndrome coronavirus infection in the who European region, June 2013
- Author
-
Pereyaslov, D., Rosin, P., Palm, D., Zeller, H., Gross, D., Brown, C. S., Struelens, M. J., Robo, A., Hatibi, I. H., Alis, J. C., Sargsyan, S., Gurbanov, S., Gribkova, N., Ranst, M., Ieven, G., Patteet, S., Tomic, S., Korsun, N., Drazenovic, V., Pieridou-Bagkatzouni, D., Jirincova, H., Havlickova, M., Fomsgaard, A., Rae, K., Lappalainen, M., Ikonen, N., Lina, B., Sylvie van der WERF, Manuguerra, J. -C, Machablishvili, A., Eickmann, M., Wolff, T., Dobler, G., Schmidt-Chanasit, J., Drosten, C., Papa, A., Mentis, A. F., Kis, Z., Löve, A., Coughlan, S., Mandelboim, M., Capobianchi, M. R., Landini, M. P., Baldanti, F., Palu, G., Ghisetti, V., Donatelli, I., Nusupbayeva, G., Tokhtabakiyeva, Z., Kasymbekova, K., Storozenko, J., Erne, S., Griskevicius, A., Opp, M., Barbara, C., Vratnica, Z., Reusken, C., Dudman, S. G., Hungnes, O., Pancer, K., Guiomar, R., Eder, V., Lupulescu, E., Yatsyshina, S., Pisareva, M., Buzitskaya, Z., Sergeev, A., Nedeljković, J., Staroňová, E., Županc, T. A., Petrovec, M., Korva, M., Prosenc, K., Casas, I., Gaines, H., Cherpillod, P., Zakirova, N., Bosevska, G., Altas, B., Ciblak, M., Mironenko, A., Dykhanovska, T., Demchyshyna, I., Bermingham, A., Rakhimov, R., Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Experts of the MERS-CoV Working Group Members of this working group who provided survey data: Albania: Alma Robo, Iris Hasibra (Hatibi), Institute of Public Health, Tirana Andorra: Josep Casals Alis, Ministry of Health, Welfare and Labour, Andorra la Vella Armenia: Shushan Sargsyan, Virology Laboratory, Centre for Diseases Control and Prevention, Yerevan Austria: Stephan Aberle, Department of Virology, Medical University of Vienna, Vienna Azerbaijan: Sadraddin Gurbanov, National Virology Laboratory, National Anti-Plague Station, Baku Belarus: Natalia Gribkova, Laboratory for Influenza and Influenza-like Diseases, Republican Research and Practical Center for Epidemiology and Microbiology, Minsk Belgium: Marc Van Ranst, Greet Ieven and Sophie Patteet, National Reference Centre of Respiratory Viruses, University Hospital Leuven and UZA Antwerpen, Antwerpen Bosnia and Herzegovina: Stanka Tomic, Microbiology Department, Institute of Public Health of the Republic of Srpska, Banja Luka Bulgaria: Neli Korsun, National Laboratory 'Influenza and ARD', Department of Virology, National Centre of Infectious and Parasitic Diseases, Sofia Croatia: Vladimir Drazenovic, National Influenza Centre, Croatian National Institute of Public Health, Zagreb Cyprus: Despo Pieridou-Bagkatzouni, Microbiology Department, Nicosia General Hospital, Nicosia Czech Republic: Helena Jirincova, Martina Havlickova, National Reference Laboratory for Influenza, National Institute for Public Health, Prague Denmark: Anders Fomsgaard, Virus Research and Development Laboratory, Department Microbiology Diagnostic and Virology, Statens Serum Institut, Copenhagen Estonia: Külli Rae, Laboratory of Communicable Diseases, Health Board, Tallinn Finland: Maija Lappalainen, Department of Virology and Immunology, Helsinki University Hospital, Laboratory Services (HUSLAB) and Niina Ikonen, Virology Unit, National Institute for Health and Welfare, Helsinki France: Bruno Lina, Centre National de Référence des Virus Influenza – HCL, Lyon and Sylvie van der Werf, Unit of Molecular Genetics of RNA viruses, Institut Pasteur and Jean-Claude Manuguerra, Cellule d’Intervention Biologique d’Urgence (CIBU), Institut Pasteur, Paris Georgia: Ann Machablishvili, National Influenza Centre, National Centre for Disease Control and Public Health, Tbilisi Germany: Markus Eickmann, Institut für Virologie der Philipps-Universität in Marburg and Thorsten Wolff, Div of Influenza and other Respiratory viruses, Robert Koch-Institut, and Dr. Gerhard Dobler, Bundeswehr Instittue of Microbiology, and Jonas Schmidt-Chanasit, WHOCC for Arbovirus and Haemorrhagic Fever Reference and Research at Bernhard Nocht Institute for Tropical Medicine, Hamburg, and Christian Drosten, Virology Institute, Bonn Greece: Anna Papa, National Reference Laboratory for Arboviruses and Hemorrhagic Fever viruses, Aristotle University of Thessaloniki, Thessaloniki and Andreas F. Mentis, National Influenza Reference Laboratory of Southern Greece/Hellenic Pasteur Institute, Athens Hungary: Zoltan Kis, Department for Respiratory Viruses / National Biosafety Laboratory, B. Johan National Center for Epidemiology, Budapest Iceland: Arthur Löve, Department of Virology, Landspitali- National University Hospital, Reykjavik Ireland: Suzie Coughlan, National Virus Reference Laboratory/University College Dublin, Dublin Israel: Michal Mandelboim, Central Virology Laboratory, Sheba Medical Center, Tel Hashomer Italy: Maria R. Capobianchi, Laboratory of Virology/National Institute for Infectious Diseases Lazzaro Spallanzani, and Maria Paola Landini, Regional Center for Emerging Infections (CRREM)/ Unit of Clinical Microbiology, St. Orsola General Hospital, Bologna, and Fausto Baldanti, Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, and Giorgio Palu, Microbiology and Virology/Padova University Hospital, and Valeria Ghisetti, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Torino, and Isabella Donatelli, National Influenza Centre, Instituto Superiore di Sanita, Kazakhstan: Gaukhar Nusupbayeva, Zarina Tokhtabakiyeva, National Reference Laboratory on Control of Viral Infections, Scientifical-Practical Center of Sanitary and Epidemiological Expertise and Monitoring, Almaty Kyrgyzstan: Kaliya Kasymbekova, Centre of Molecular-Genetic and Microbiological Investigations, Department of State Sanitary Epidemiological Surveillance, Bishkek Latvia: Jelena Storozenko, Riga East University Hospital, Latvian Centre of Infectious Diseases, National Microbiology Reference Laboratory, Riga Liechtenstein: Sabine Erne, Office of Public Health, Country Administration of Principality of Liechtenstein Lithuania: Algirdas Griskevicius, National Public Health Surveillance Laboratory, Vilnius Luxembourg: Matthias Opp, Laboratoire National de Santé, Luxembourg Malta: Christopher Barbara, Pathology Department, Mater Dei Hospital, Msida Montenegro: Zoran Vratnica, Centre for Medical Microbiology, Public Health Institute of Montenegro, Podgorica Netherlands: Chantal Reusken, Centre for Infectious Disease Research, Diagnostics and Screening, National Institute for Public Health and the Environment, Bilthoven Norway: Susanne Gjeruldsen Dudman and Olav Hungnes, Department of Virology, Norwegian Institute of Public Health, Oslo Poland: Katarzyna Pancer, National Institute of Public Health- National Institute of Hygiene, Department of Virology, Warsaw Portugal: Raquel Guiomar, National Influenza Reference Laboratory, Infectious Diseases Department, National Institute of Health, Lisboa Republic of Moldova: Veronica Eder, Laboratory of Viral Respiratory Infections, National Center for Public Health, Chisinau Romania: Emilia Lupulescu, Laboratory for Respiratory Viruses/ NIRDMI Cantacuzino, Bucharest Russian Federation: Svetlana Yatsyshina, Reference Centre for Infection Agents, Central Research Institute of Epidemiology (CRIE), Rospotrebnadzor, Moscow, and Maria Pisareva and Zhanna Buzitskaya, Laboratory of Molecular Virology and Genetic Engineering, Research Institute of Influenza, St Petersburg, and Alexander Sergeev, State Research Center of Virology and Biotechnology VECTOR, Novosibirsk Serbia: Jasminka Nedeljković, Respiratory Department, Torlak Institute of Immunology and Virology, Belgrade Slovakia: Edita Staroňová, National Influenza Center/Public Health Authority, Bratislava Slovenia: Tatjana Avšič Županc, Miroslav Petrovec, Miša Korva, University of Ljubljana, Faculty of Medicine, Institute of Microbiology and Immunology, and Katarina Prosenc, Laboratory for Virology, National Public Health Institute Slovenia, Ljubljana Spain: Inmaculada Casas, Influenza National Reference Laboratory, National Influenza Center-Madrid, Instituto de Salud Carlos III, Majadahonda, Madrid and Ramon Cisterna Clinical microbiology and infection control, Hospital Basurto Bilbao Spain Sweden: Hans Gaines, Swedish Institute for Communicable Disease Control, Stockholm Switzerland: Pascal Cherpillod, National Reference Centre for Emerging Viral Infections, Laboratory of Virology, Division of Infectious Diseases University of Geneva Hospitals, Geneva Tajikistan: Niginamo Zakirova, Virology Laboratory, State Sanitary-Epidemiological Surveillance, Dushanbe The former Yugoslav Republic of Macedonia: Golubinka Bosevska, Laboratory for Virology and Molecular Diagnostics, Institute of Public Health, Skopje Turkey: Basak Altas, National Influenza Centre, Virology Reference and Research Laboratory, Public Health Institutions of Turkey, Ankara, and Meral Ciblak, National Influenza Reference Laboratory, Faculty of Medicine, University of Istanbul, Istanbul Turkmenistan: Central Reference Laboratory, Sanitary Epidemiologic Service, Ashgabat Ukraine: Alla Mironenko, National Influenza Centre, L.V.Gromashevsky Institute of Epidemiology & Infectious diseases NAMS, and Tetiana Dykhanovska and Iryna Demchyshyna, Centre of influenza and ARVI, Central Sanitary and Epidemiological Station, Kiev United Kingdom: Alison Bermingham, Respiratory Virus Unit, Virus Reference Department, Public Health England, London Uzbekistan: Ravshan Rakhimov, National Influenza Centre, Institute of Virology, Tashkent., and We thank the ECDC National Microbiology Focal Points in EU/EEA countries, focal points from laboratories of the EuroFlu and ENIVD networks for coordinating data collection and for dedicated and rapid responses to the surveys.
- Subjects
Epidemiology ,Middle East respiratory syndrome coronavirus ,[SDV]Life Sciences [q-bio] ,SARS (Disease) ,MERS (Disease) ,medicine.disease_cause ,World Health Organization ,Communicable Diseases, Emerging ,World health ,Viral genetics ,Coronavirus infections -- Laboratory manuals ,Environmental protection ,Virology ,Environmental health ,medicine ,media_common.cataloged_instance ,Humans ,European Union ,European union ,Coronavirus ,media_common ,Middle East ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Public Health, Environmental and Occupational Health ,Reference Standards ,European region ,Health Surveys ,Diseases -- Causes and theories of causation ,Middle East Respiratory Syndrome Coronavirus ,RNA, Viral ,Disease prevention ,business ,Coronavirus Infections ,Laboratories ,Sentinel Surveillance ,Sequence Analysis - Abstract
Since September 2012, over 90 cases of respiratory disease caused by a novel coronavirus, now named Middle East respiratory syndrome coronavirus (MERS-CoV), have been reported in the Middle East and Europe. To ascertain the capabilities and testing experience of national reference laboratories across the World Health Organization (WHO) European Region to detect this virus, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe conducted a joint survey in November 2012 and a follow-up survey in June 2013. In 2013, 29 of 52 responding WHO European Region countries and 24 of 31 countries of the European Union/European Economic Area (EU/EEA) had laboratory capabilities to detect and confirm MERS-CoV cases, compared with 22 of 46 and 18 of 30 countries, respectively, in 2012. By June 2013, more than 2,300 patients had been tested in 23 countries in the WHO European Region with nine laboratory-confirmed MERS-CoV cases. These data indicate that the Region has developed significant capability to detect this emerging virus in accordance with WHO and ECDC guidance. However, not all countries had developed capabilities, and the needs to do so should be addressed. This includes enhancing collaborations between countries to ensure diagnostic capabilities for surveillance of MERS-CoV infections across the European Region., peer-reviewed
- Published
- 2014
6. European survey on laboratory preparedness, response and diagnostic capacity for crimean-congo haemorrhagic fever, 2012
- Author
-
Fernandez-Garcia, M.D. (Maria Dolores), Negredo, A., Papa, A. (Anna), Donoso-Mantke, O., Niedrig, M., Zeller, H. (Hervé), Tenorio, A., Franco, L. (Leticia), Aberle, S.W. (Stephan), Esbroeck, M. (M.) van, Christova, I., Markotic, A. (Alemka), Kurolt, I.-C. (Ivan-Christian), Zelena, H. (Hana), Golovljova, I., Pannetier, D. (Delphine), Charrel, R. (Remi), Schmidt-Chanasit, J. (Jonas), Wölfel, R. (Roman), Capobianchi, M.R. (Maria Rosaria), Jakupi, X. (Xhevat), Storozenko, J. (Jelena), Griskevicius, A. (Algirdas), Bosevska, G. (Golubinka), Muscat, C. (Clive), Schutten, M. (Martin), Dudman, S.G. (Susanne Gjeruldsen), Alves, M.J. (M. João), Ceianu, C.S., Platonov, A. (Alexander), Bozovic, B. (Bojana), Klempa, B., Avsic, T. (Tatjana), Lundkvist, Å. (Åke), Cherpillod, P. (Pascal), Korukluoglu, G., Brown, D.W.G. (D. W G), Brooks, T. (Tim), Fernandez-Garcia, M.D. (Maria Dolores), Negredo, A., Papa, A. (Anna), Donoso-Mantke, O., Niedrig, M., Zeller, H. (Hervé), Tenorio, A., Franco, L. (Leticia), Aberle, S.W. (Stephan), Esbroeck, M. (M.) van, Christova, I., Markotic, A. (Alemka), Kurolt, I.-C. (Ivan-Christian), Zelena, H. (Hana), Golovljova, I., Pannetier, D. (Delphine), Charrel, R. (Remi), Schmidt-Chanasit, J. (Jonas), Wölfel, R. (Roman), Capobianchi, M.R. (Maria Rosaria), Jakupi, X. (Xhevat), Storozenko, J. (Jelena), Griskevicius, A. (Algirdas), Bosevska, G. (Golubinka), Muscat, C. (Clive), Schutten, M. (Martin), Dudman, S.G. (Susanne Gjeruldsen), Alves, M.J. (M. João), Ceianu, C.S., Platonov, A. (Alexander), Bozovic, B. (Bojana), Klempa, B., Avsic, T. (Tatjana), Lundkvist, Å. (Åke), Cherpillod, P. (Pascal), Korukluoglu, G., Brown, D.W.G. (D. W G), and Brooks, T. (Tim)
- Abstract
Crimean-Congo haemorrhagic fever (CCHF) is an infectious viral disease that has (re-)emerged in the last decade in south-eastern Europe, and there is a risk for further geographical expansion to western Europe. Here we report the results of a survey covering 28 countries, conducted in 2012 among the member laboratories of the European Network for Diagnostics of 'Imported' Viral Diseases (ENIVD) to assess laboratory preparedness and response capacities for CCHF. The answers of 31 laboratories of the European region regarding CCHF case definition, training necessity, biosafety, quality assurance and diagnostic tests are presented. In addition, we identifie
- Published
- 2014
7. European survey on laboratory preparedness, response and diagnostic capacity for crimean-congo haemorrhagic fever, 2012
- Author
-
Fernandez-García, M.D., Negredo, A., Papa, Anna, Donoso-Mantke, O., Niedrig, M., Zeller, H., Tenorio, A., Franco, L., Aberle, S., van Esbroeck, M., Christova, I., Markotić, A., Kurolt, I.-C., Zelena, H., Golovljova, I., Pannetier, D., Charrel, R., Schmidt-Chanasit, J., Wölfel, R., Capobianchi, M.R., Jakupi, X., Storozenko, J., Griskevicius, A., Bosevska, G., Muscat, C., Schutten, M., Dudman, S.G., Alves, M.J., Ceianu, C., Platonov, A., Božović, Bojana, Klempa, B., Avsić, T., Lundkvist, A., Cherpillod, P., Korukluoglu, G., Brown, D., Brooks, T., Fernandez-García, M.D., Negredo, A., Papa, Anna, Donoso-Mantke, O., Niedrig, M., Zeller, H., Tenorio, A., Franco, L., Aberle, S., van Esbroeck, M., Christova, I., Markotić, A., Kurolt, I.-C., Zelena, H., Golovljova, I., Pannetier, D., Charrel, R., Schmidt-Chanasit, J., Wölfel, R., Capobianchi, M.R., Jakupi, X., Storozenko, J., Griskevicius, A., Bosevska, G., Muscat, C., Schutten, M., Dudman, S.G., Alves, M.J., Ceianu, C., Platonov, A., Božović, Bojana, Klempa, B., Avsić, T., Lundkvist, A., Cherpillod, P., Korukluoglu, G., Brown, D., and Brooks, T.
- Abstract
Crimean-Congo haemorrhagic fever (CCHF) is an infectious viral disease that has (re-)emerged in the last decade in south-eastern Europe, and there is a risk for further geographical expansion to western Europe. Here we report the results of a survey covering 28 countries, conducted in 2012 among the member laboratories of the European Network for Diagnostics of 'Imported' Viral Diseases (ENIVD) to assess laboratory preparedness and response capacities for CCHF. The answers of 31 laboratories of the European region regarding CCHF case definition, training necessity, biosafety, quality assurance and diagnostic tests are presented. In addition, we identified the lack of a Regional Reference Expert Laboratory in or near endemic areas. Moreover, a comprehensive review of the biosafety level suitable to the reality of endemic areas is needed. These issues are challenges that should be addressed by European public health authorities. However, all respondent laboratories have suitable diagnostic capacities for the current situation.
- Published
- 2014
8. Ongoing outbreak of aseptic meningitis in south-eastern Latvia, June – August 2010
- Author
-
Perevoščikovs, J, primary, Brila, A, additional, Firstova, L, additional, Komarova, T, additional, Lucenko, I, additional, Osmjana, J, additional, Savrasova, L, additional, Singarjova, I, additional, Storozenko, J, additional, Voloscuka, N, additional, and Zamjatina, N, additional
- Published
- 2010
- Full Text
- View/download PDF
9. Prevalence of resistance associated mutations in treatment-experienced HIV infected individuals in Latvia
- Author
-
Guseva, L., primary, Dusacka, D., additional, Kolupajeva, T., additional, Storozenko, J., additional, Sture, G., additional, and Rozentale, B., additional
- Published
- 2006
- Full Text
- View/download PDF
10. European survey on laboratory preparedness, response and diagnostic capacity for crimean-congo haemorrhagic fever, 2012
- Author
-
Fernandez-García, M. D., Negredo, A., Papa, A., Donoso-Mantke, O., Niedrig, M., Zeller, H., Tenorio, A., Franco, L., Aberle, S., Esbroeck, M., Christova, I., Markotic, A., Kurolt, I. -C, Zelena, H., Golovljova, I., Pannetier, D., Charrel, R., Schmidt-Chanasit, J., Wölfel, R., Maria Rosaria Capobianchi, Jakupi, X., Storozenko, J., Griskevicius, A., Bosevska, G., Muscat, C., Schutten, M., Dudman, S., Alves, M. J., Ceianu, C., Platonov, A., Bozovic, B., Klempa, B., Avsic, T., Lundkvist, A., Cherpillod, P., Korukluoglu, G., Brown, D., and Brooks, T.
11. European survey on laboratory preparedness, response and diagnostic capacity for Crimean-Congo haemorrhagic fever, 2012
- Author
-
Fernandez-García, M.D., Negredo, A., Papa, Anna, Donoso-Mantke, O., Niedrig, M., Zeller, H., Tenorio, A., Franco, L., Aberle, S., van Esbroeck, M., Christova, I., Markotić, A., Kurolt, I.-C., Zelena, H., Golovljova, I., Pannetier, D., Charrel, R., Schmidt-Chanasit, J., Wölfel, R., Capobianchi, M.R., Jakupi, X., Storozenko, J., Griskevicius, A., Bosevska, G., Muscat, C., Schutten, M., Dudman, S.G., Alves, M.J., Ceianu, C., Platonov, A., Božović, Bojana, Klempa, B., Avsić, T., Lundkvist, A., Cherpillod, P., Korukluoglu, G., Brown, D., and Brooks, T.
- Subjects
medicine.medical_specialty ,Laboratory Proficiency Testing ,Civil defense ,Epidemiology ,Crimean-Congo haemorrhagic fever ,VDP::Medisinske fag: 700::Helsefag: 800::Epidemiologi medisinsk og odontologisk statistikk: 803 ,Haemorragic Fever ,Communicable diseases ,Biosafety ,Tropical medicine ,Environmental protection ,Virology ,Environmental health ,Biosafety level ,Medicine ,Humans ,Diagnostic ,Infecções Sistémicas e Zoonoses ,business.industry ,Public health ,Public Health, Environmental and Occupational Health ,Civil Defense ,Medical microbiology ,Health Surveys ,Europe ,Diagnostic virology -- Laboratory manuals ,Preparedness ,European Survey ,Population Surveillance ,Respondent ,Hemorrhagic Fever Virus, Crimean-Congo ,Crimean-Congo ,Hemorrhagic Fever, Crimean ,VDP::Midical sciences: 700::Health sciences: 800::Epidemiology, medical and dental statistics: 803 ,business ,Laboratories - Abstract
Crimean-Congo haemorrhagic fever (CCHF) is an infectious viral disease that has (re-)emerged in the last decade in south-eastern Europe, and there is a risk for further geographical expansion to western Europe. Here we report the results of a survey covering 28 countries, conducted in 2012 among the member laboratories of the European Network for Diagnostics of 'Imported' Viral Diseases (ENIVD) to assess laboratory preparedness and response capacities for CCHF. The answers of 31 laboratories of the European region regarding CCHF case definition, training necessity, biosafety, quality assurance and diagnostic tests are presented. In addition, we identified the lack of a Regional Reference Expert Laboratory in or near endemic areas. Moreover, a comprehensive review of the biosafety level suitable to the reality of endemic areas is needed. These issues are challenges that should be addressed by European public health authorities. However, all respondent laboratories have suitable diagnostic capacities for the current situation., peer-reviewed
12. Association of human leukocyte antigen class II alleles with epithelial cell apoptosis and extracellular matrix production in acute COVID-19.
- Author
-
Vanaga I, Kolesova O, Kolesovs A, Sture G, Hagina E, Storozenko J, Nikitina-Zake L, and Viksna L
- Abstract
Introduction: Pathogenic mechanisms and long-term consequences of COVID-19 require attention in studies on SARS-CoV-2. The association of the severity of COVID-19 with genetic factors, such as human leukocyte antigen (HLA) genes, remains underexplored. Our study assessed the relationships between HLA class II alleles and COVID-19 severity and blood-based indicators of systemic inflammation and organ damage, serum markers of epithelial cell apoptosis such as caspase-cleaved CK18 fragment M30 (CK18-M30) and the extracellular matrix product hyaluronic acid (HA)., Material and Methods: The study included 101 hospitalized COVID-19 patients (mean age 60 ±14 years). Clinical tests were performed at admission to the hospital. The levels of CK18-M30 and HA were detected in serum by enzyme-linked immunosorbent assay (ELISA). HLA typing was performed in HLA-DRB1, -DQA1, and -DQB1 loci by the polymerase chain reaction with low-resolution sequence-specific primers., Results: Sixty-one patients had a non-severe and 40 had a severe or critical disease course (following the WHO definition). The severity was associated with older age, male gender, higher HA, CK18-M30, and some indicators of inflammation. Despite the lack of direct association between HLA alleles and the severity of COVID-19, the presence of HLA-DRB1*04 and 12 alleles in the genotype was associated with lowered or elevated HA, respectively. The HLA-DQB1*03:01 allele was associated with lowered CK18-M30, aspartate aminotransferase, and ferritin. In addition, HLA-DQB1*06:01 was associated with elevated alanine aminotransferase., Conclusions: Associations of HLA class II alleles with markers of epithelial cell apoptosis and extracellular matrix production indirectly support the influence of HLA genes on acute COVID-19 severity., Competing Interests: The authors declare no conflict of interest., (Copyright © 2023 Termedia.)
- Published
- 2023
- Full Text
- View/download PDF
13. Molecular epidemiology of hepatitis A outbreaks and sporadic cases, Latvia, 2017 to 2019.
- Author
-
Savicka O, Zeltmatis R, and Storozenko J
- Subjects
- Disease Outbreaks, Female, Genotype, Homosexuality, Male, Humans, Latvia epidemiology, Male, Molecular Epidemiology, Phylogeny, RNA, Viral genetics, Hepatitis A diagnosis, Hepatitis A epidemiology, Hepatitis A virus genetics, Sexual and Gender Minorities
- Abstract
BackgroundHepatitis A is an acute infection of the liver caused by hepatitis A virus (HAV). Molecular detection and typing of the HAV VP1/P2A genomic region is used for genotyping and outbreak investigations. After a large hepatitis A outbreak in Latvia in 2007-08, only sporadic cases were registered until 2017 when a rise in cases occurred. During 2017-19, 179 laboratory-confirmed hepatitis A cases were notified in Latvia.AimTo investigate the observed increase in hepatitis A cases during 2017 and to determine whether these cases were linked to one another, to risk groups, or to other outbreaks. The majority of HAV samples (69.8%) were typed.MethodsThe VP1/P2A genomic region of HAV was amplified and sequenced for 125 case serum samples. Information about hepatitis-related symptoms, hospitalisation, vaccination, a possible source of infection and suspected countries of origin of the virus were analysed for sequenced cases.ResultsMost HAV strains were subgenotype IA (n = 77), of which 41 were strains circulating among men who have sex with men (MSM) populations in Europe (VRD_521_2016 (n = 32), RIVM-HAV16-090 (n = 7) or V16-25801 (n = 2)). Forty-four cases were subgenotype IB and four cases subgenotype IIIA. However, other clusters and sporadic cases were detected with or without identifying the epidemiological link.ConclusionThis work represents molecular epidemiological data of hepatitis A cases in Latvia from 2017 to 2019. Molecular typing methods allow identification of clusters for public health needs and establishing links with other outbreaks, and to compare Latvian strains with reported strains from other countries.
- Published
- 2022
- Full Text
- View/download PDF
14. Intriguing findings of liver fibrosis following COVID-19.
- Author
-
Kolesova O, Vanaga I, Laivacuma S, Derovs A, Kolesovs A, Radzina M, Platkajis A, Eglite J, Hagina E, Arutjunana S, Putrins DS, Storozenko J, Rozentale B, and Viksna L
- Subjects
- Adult, Aged, Aspartate Aminotransferases, Female, Humans, Liver Cirrhosis, Male, Middle Aged, SARS-CoV-2, COVID-19, Elasticity Imaging Techniques
- Abstract
Background: Studies on a new coronavirus disease (COVID-19) show the elevation of liver enzymes and liver fibrosis index (FIB-4) independently on pre-existing liver diseases. It points to increased liver fibrogenesis during acute COVID-19 with possible long-term consequences. This study aimed to assess liver fibrosis in COVID-19 patients by serum hyaluronic acid (HA) and FIB-4., Methods: The study included the acute COVID-19 group (66 patients, 50% females, mean age 58.3 ± 14.6), the post-COVID group (58 patients in 3-6 months after the recovery, 47% females, mean age 41.2 ± 13.4), and a control group (17 people, 47% females, mean age 42.8 ± 11.0). Ultrasound elastography was performed in the post-COVID and control groups., Results: Sixty-five percent of the acute COVID-19 group had increased FIB-4 (> 1.45), and 38% of patients had FIB-4 ≥ 3.25. After matching by demographics, 52% of acute COVID-19 and 5% of the post-COVID group had FIB-4 > 1.45, and 29% and 2% of patients had FIB-4 ≥ 3.25, respectively. Increased serum HA (≥ 75 ng/ml) was observed in 54% of the acute COVID-19 and 15% of the post-COVID group. In the acute COVID-19 group, HA positively correlated with FIB-4, AST, ALT, LDH, IL-6, and ferritin and negatively with blood oxygen saturation. In the post-COVID group, HA did not correlate with FIB-4, but it was positively associated with higher liver stiffness and ALT., Conclusion: More than half of acute COVID-19 patients had increased serum HA and FIB-4 related to liver function tests, inflammatory markers, and blood oxygen saturation. It provides evidence for the induction of liver fibrosis by multiple factors during acute COVID-19. Findings also indicate possible liver fibrosis in about 5% of the post-COVID group., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
15. First Report on the Latvian SARS-CoV-2 Isolate Genetic Diversity.
- Author
-
Zrelovs N, Ustinova M, Silamikelis I, Birzniece L, Megnis K, Rovite V, Freimane L, Silamikele L, Ansone L, Pjalkovskis J, Fridmanis D, Vilne B, Priedite M, Caica A, Gavars M, Perminov D, Storozenko J, Savicka O, Dimina E, Dumpis U, and Klovins J
- Abstract
Remaining a major healthcare concern with nearly 29 million confirmed cases worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 920 thousand deaths since its outbreak in China, December 2019. First case of a person testing positive for SARS-CoV-2 infection within the territory of the Republic of Latvia was registered on 2nd of March 2020, 9 days prior to the pandemic declaration by WHO. Since then, more than 277,000 tests were carried out confirming a total of 1,464 cases of coronavirus disease 2019 (COVID-19) in the country as of 12th of September 2020. Rapidly reacting to the spread of the infection, an ongoing sequencing campaign was started mid-March in collaboration with the local testing laboratories, with an ultimate goal in sequencing as much local viral isolates as possible, resulting in first full-length SARS-CoV-2 isolate genome sequences from the Baltics region being made publicly available in early April. With 133 viral isolates representing ~9.1% of the total COVID-19 cases during the "first coronavirus wave" in the country (early March, 2020-mid-September, 2020) being completely sequenced as of today, here, we provide a first report on the genetic diversity of Latvian SARS-CoV-2 isolates., Competing Interests: MP and AC were employed by the company Central Laboratory Ltd, Latvia. MG and DP were employed by the company E. Gulbja Laboratorija, Ltd, Latvia. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Zrelovs, Ustinova, Silamikelis, Birzniece, Megnis, Rovite, Freimane, Silamikele, Ansone, Pjalkovskis, Fridmanis, Vilne, Priedite, Caica, Gavars, Perminov, Storozenko, Savicka, Dimina, Dumpis and Klovins.)
- Published
- 2021
- Full Text
- View/download PDF
16. Analysis of Mycobacterium tuberculosis genetic lineages circulating in Riga and Riga region, Latvia, isolated between 2008 and 2012.
- Author
-
Pole I, Trofimova J, Norvaisa I, Supply P, Skenders G, Nodieva A, Ozere I, Riekstina V, Igumnova V, Storozenko J, Jansone I, Viksna L, and Ranka R
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antitubercular Agents pharmacology, Child, Child, Preschool, Drug Resistance, Multiple, Bacterial drug effects, Drug Resistance, Multiple, Bacterial genetics, Female, Genetic Variation, Genotyping Techniques, Humans, Infant, Infant, Newborn, Latvia epidemiology, Male, Microbial Sensitivity Tests, Middle Aged, Minisatellite Repeats, Molecular Epidemiology, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis isolation & purification, Polymorphism, Restriction Fragment Length, Prevalence, Tuberculosis, Multidrug-Resistant epidemiology, Tuberculosis, Multidrug-Resistant microbiology, Young Adult, Mycobacterium tuberculosis genetics, Tuberculosis epidemiology, Tuberculosis microbiology
- Abstract
Although the number of new tuberculosis (TB) cases registered per year has decreased by 3-fold between 2001 and 2017 in Latvia, the TB incidence and rates of multidrug resistant TB in this Baltic country remain substantially higher than in most other European countries. Molecular typing methods of Mycobacterium tuberculosis (MTB) play an important role both in clinical studies of the disease and the epidemiological investigations, allowing to describe and characterize the pathogen's population structure and spread of particular genotypes. Aim of this study was to examine the prevalence of MTB lineages in Riga and Riga region of Latvia within a five-year period (2008-2012), and to evaluate the discriminatory power (DP) of spoligotyping, standard 24-locus MIRU-VNTR and IS6110-RFLP methods in this setting. The results showed that the main MTB spoligotype families were Beijing (25.3%) and LAM (24.3%), followed by T (22.1%), Ural (11.2%), Haarlem (6.6%) and X superfamily (3.4%). This distribution remained stable over the five consecutive years. 67.6% of MTB isolates were pan-susceptible, and 32.4% were resistant to any drug; multi-drug resistance was found in 5.8% of MTB strains, and 7.6% of MTB isolates were extensively drug-resistant. Drug resistance was associated with SIT1, SIT283 and SIT42 genotypes, while SIT1 and SIT42 were overrepresented among multi drug-resistant MTB strains. Overall, DP of spoligotyping method alone was 0.8953, while DP of both 24-locus MIRU-VNTR analysis and IS6110 RFLP was higher (DP = 0.9846 and 0.9927, respectively), mainly due to the improvement of the resolution for the Beijing strains. In conclusion, this work represents the first comprehensive molecular epidemiological description of TB in Latvia, highlighting the high genetic diversity of MTB strains circulating in Riga and Riga region. In combination with detailed epidemiological data this approach was helpful for the in-depth understanding of epidemiological processes in settings where the Next-Gen sequencing is not available as a routine method., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. Tick-borne encephalitis: A 43-year summary of epidemiological and clinical data from Latvia (1973 to 2016).
- Author
-
Zavadska D, Odzelevica Z, Karelis G, Liepina L, Litauniece ZA, Bormane A, Lucenko I, Perevoscikovs J, Bridina L, Veide L, Krumina A, Storozenko J, Erber W, Htar MTT, and Schmitt HJ
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Encephalitis, Tick-Borne prevention & control, Female, Humans, Incidence, Latvia epidemiology, Male, Middle Aged, Retrospective Studies, Sex Factors, Databases, Factual, Encephalitis, Tick-Borne epidemiology
- Abstract
Background: The incidence of tick-borne encephalitis (TBE) varies significantly over time. To better understand the annual incidence of all TBE cases in Latvia we investigated the disease burden in the country from 1973-2016 using several available sources and case definitions., Methods: We identified cases of TBE from an electronic database (maintained by the Centre for Disease Prevention and Control of Latvia [CDPC]) by the use of ICD-10 diagnosis codes for TBE (A84; A84.0; A84.1; A84.8; A84.9). In addition, previously unreported TBE cases were found by review of TBE diagnoses according to ICD-10 codes in four hospital databases., Results: From 1973 to 2016 a total of 15,193 TBE cases were reported to the CDPC, 2,819 of which were reported from January 2007 through December 2016, additionally for this time period, 104 cases were identified via hospital survey. From all 2,923 reported cases (2007-2016), 1,973 met TBE case definition criteria and were included in the TBE study analysis. The highest average 10 year incidence was observed from 1990-1999 (27.9 cases per 100,000; range 4.6-53.0), however, the average 10-year incidence from 2007-2016 using officially adopted TBE case definition was 9.6 cases per 100,000 (range 5.8-14.6). For this 10-year time period most cases were adults (95.1%) and male (52.2%). The most common clinical form of TBE was meningitis (90.6%). A tick bite prior to TBE onset was reported in 60.6% of TBE cases and 98.2% of cases were not vaccinated against TBE., Conclusion: The data demonstrate that the incidence of TBE varies by about one third based on the case definition used. TBE occurs almost entirely in the unvaccinated population. Regular TBE awareness campaigns could encourage the population in Latvia to use protective measures to further control TBE in the country, either via vaccination or tick avoidance., Competing Interests: HJS, WE, MTTH are full time employees of Pfizer. No relevant conflict of interests for other authors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.